MEDP logo

MEDPACE HOLDINGS INC

MEDPNASDAQ
πŸ† #545 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track MEDP
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$18.93B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
20.4%
Healthy
πŸ“ŠGross Margin
29.1%
Moderate
πŸ’΅FCF Margin
23.5%
Strong
βš–οΈP/S Ratio
6.6x
Fair
Otter Score
72
Strong
No chart data available for MEDP.

Trading Snapshot

Day Range
β€”
52-Week Range
$373.00 – $684.52
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
28.0M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
36.4
P/S Ratio
6.6x
EPS (TTM)
$18.04
Dividend Yield
β€”
Dilution (1yr)
βˆ’9.5%
MEDP logo

MEDPACE HOLDINGS INC

MEDP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.5Bβ–² +20.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
30.1%β–Ό βˆ’3.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$535Mβ–² +19.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$682Mβ–² +19.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
29.0Mβ–Ό βˆ’9.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$360Mβ–Ό βˆ’$160M YoY
StockOtter Β· stockotter.space

About MEDPACE HOLDINGS INC

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

News unavailable.